When are Psychotherapy and Pharmacotherapy Combinations the Treatment of Choice for Major Depressive Disorder?

  title={When are Psychotherapy and Pharmacotherapy Combinations the Treatment of Choice for Major Depressive Disorder?},
  author={Michael E. Thase},
  journal={Psychiatric Quarterly},
  • M. Thase
  • Published 2004
  • Psychology
  • Psychiatric Quarterly
Treating major depressive disorder with the combination of psychotherapy and pharmacotherapy is highly valued by both psychiatrists and their patients. However, results of most systematic research studies suggest that this approach may be overvalued: evidence of additive benefits (in relation to the respective component therapies, alone) is meager. In this paper it is argued that the advantage of combined treatment may be limited to treatment of patients with more complex depressive disorders… 
Should combined pharmaco- and psychotherapy be offered to depressed patients?
It is shown that a COMBI is superior to interpersonal psychotherapy but not superior to medication alone, however, certain subgroups of patients might benefit substantially from COMBI compared to both psychotherapy and pharmacotherapy alone.
[Re: Inpatient treatment of depression. Should one combine psychotherapy and drugs?].
  • Huber Tj
  • Psychology, Medicine
    Der Nervenarzt
  • 2005
A critical overview of the evidence base for combination therapy in the inpatient treatment of depression appears advantageous in therapy-resistant, chronic and severe forms of depressive disorders.
Combined Treatment of Major Depression in Patients with Borderline Personality Disorder: A Comparison with Pharmacotherapy
Combined therapy with IPT is more effective than antidepressant therapy alone, both in treating symptoms of major depression and in improving dimensions of quality of life and interpersonal functioning.
Treatment strategies to improve and sustain remission in major depressive disorder
Major depressive disorder (MDD) is an often chronic, recurrent illness affecting large numbers of the general population. In recent years, the goal of treatment for MDD has moved from mere
Treatment strategies to improve and sustain remission in major depressive disorder.
Some current treatment strategies available to improve rates of, and to sustain, remission in MDD are reported on.
A naturalistic trial of brief psychodynamic therapy for recurrent major depression.
Patients who received augmented treatment but showed no evidence of recovery scored significantly higher on indices of alexithymia and patient clusters showed distinct trajectories of change on the Hamilton Rating Scale for Depression over the year after referral.
Treatment for Chronic Depression Using Schema Therapy
Schema therapy (ST) is an integrative treatment approach to chronic lifelong problems with an established effectiveness for treating personality disorders. This article describes the adaptation of ST
Depression treatment in primary care.
Pharmacotherapy was found to be the most widely used treatment despite current evidence-based recommendations, and the negotiation process during the patient-provider encounter would shed light on patient and physician factors influencing treatment decisions.
An Investigation of Atypical Antidepressants
  • Psychology
  • 2010
In modern Psychiatric practice, the vast majority of patients diagnosed with Major Depression are given a Selective Serotonin Reuptake Inhibitor (SSRI). Although SSRIs are generally regarded as safe
Systemic Assessment and Treatment of Depression and Anxiety in Families: The BPSS Model in Practice
The purpose of this paper is to describe a collaborative and integrative multisystemic approach to the assessment and treatment of mood and anxiety disorders based on the bio-psycho-social-spiritual


Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations.
New evidence is found in support of the widespread clinical impression that combined therapy is superior to psychotherapy alone for treatment of more severe, recurrent depressions.
Cognitive Therapy for Major Depressive Disorder in Primary Care
At three-month follow-up cognitive therapy patients no longer differed from patients receiving treatment-as-usual, but this was mainly as a result of continuing improvement in the comparison group.
Cognitive therapy and pharmacotherapy for depression. Singly and in combination.
Combining cognitive therapy with pharmacotherapy did not markedly improve response over that observed for either modality alone, although such nonsignificant differences as were evident did favor the combined treatment.
The role of Axis II comorbidity in the management of patients with treatment-resistant depression.
  • M. Thase
  • Psychology
    The Psychiatric clinics of North America
  • 1996
The Efficacy of Cognitive Therapy in Depression: A Treatment Trial Using Cognitive Therapy and Pharmacotherapy, each Alone and in Combination
An extensive study which compares cognitive therapy, antidepressant drugs and a combination of these two, in depressed patients seen either in general practice or an out-patient department and results are discussed in terms of Beck's cognitive theory of depression.
Cognitive-behavioral management of drug-resistant major depressive disorder.
BACKGROUND The application of cognitive-behavioral treatment to drug-resistant major depression has received little research attention. METHOD Nineteen patients who failed to respond to at least
The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: integrating psychological and biological factors
The key finding is that high specificity is of significant prophylactic benefit even for patients with a biological vulnerability for recurrence, and high treatment specificity is, in turn, reflected in longer times to recurrence.
Predictors of drug response in depression.
Clinical and biologic predictors of response, despite some interesting leads that may in the long term be of considerable importance, are not yet sufficiently established to be of routine clinical usefulness, although either dexamethasone nonsuppression or a shortened rapid eye movement latency may identify depressed patients who require biologic treatment.
Treating major depression in primary care practice. Eight-month clinical outcomes.
Severity of depressive symptoms was reduced more rapidly and more effectively among patients randomized to pharmacotherapy or psychotherapy than among patients assigned to a physician's usual care.